Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | GSTK1 | Q9Y2Q3 | 1/20 | 0.58 |
| ▸ | GLP1R | P43220 | 8/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.46 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.44 |
| ▸ | FNTA | P49354 | 1/20 | 0.42 |
| ▸ | FNTB | P49356 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8933698 | 1.00 | NOD1 (0.58) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL2787327 | 1.00 | NOD1 (0.58) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL27640167 | 1.00 | NOD1 (0.58) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL2048450 | 0.99 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL28851364 | 0.99 | PTGS1 (0.59) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL3798423 | 0.96 | PTGS1 (0.62) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL28180347 | 0.96 | PTGS1 (0.62) | NOD1PTGS1GSTK1GLP1REPHX2 | |
| SCHEMBL1503473 | 0.91 | PTGS1 (0.63) | NOD1PTGS1GSTK1GLP1RGLO1 | |
| SCHEMBL3800861 | 0.90 | NOD1 (0.65) | NOD1PTGS1GSTK1GLP1R | |
| SCHEMBL3796046 | 0.90 | NOD1 (0.65) | NOD1PTGS1GSTK1GLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2398500-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB Holding B.V. (NL) | 2011-12-28 | — | — | EP | claimed |
| WO-2010095940-A2 | GLUTATHIONE-BASED DRUG DELIVERY SYSTEM | TO-BBB HOLDING B.V. (NL) | 2010-08-26 | — | — | WO | claimed |
| EP-3270889-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | Mireca Medicines GmbH (DE) | 2018-01-24 | — | — | EP | disclosed |
| WO-2016146669-A1 | TARGETED LIPOSOMAL DELIVERY OF CGMP ANALOGUES | EBERHARD KARLS UNIVERSITÄT TÜBINGEN (DE) | 2016-09-22 | — | — | WO | disclosed |
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | UNIVERSITATSKLINIKUM MUNSTER (DE) | 2008-06-26 | — | — | US | disclosed |
| WO-2002059142-A2 | POLYMORPHISMS IN THE HUMAN GENE FOR THE MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1 (MRP-1) AND THEIR USE IN DIAGNOSTIC AND THERAPEUTIC APPLICATIONS | EPIDAUROS BIOTECHNOLOGIES AG (DE) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080152640-A1 | Means and Methods For Treating a Disease Which is Associated With an Excess Transport of Hyaluronan Across a Lipid Bilayer | ABCB1, ABCB11, SLC47A2 | NOD1 1684/4885PTGS1 1544/4885GSTK1 1871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.